Latest News and Press Releases

MONTRÉAL, 30 mars 2026 (GLOBE NEWSWIRE) -- Le CN (TSX : CNR) (NYSE : CNI) divulguera ses résultats financiers et d’exploitation du premier trimestre de 2026 avant l’ouverture des marchés le 29...

MONTREAL, March 30, 2026 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) will issue its first-quarter 2026 financial and operating results before the markets open on April 29, 2026. CN's senior...

New Product Line Targets Estimated $185–$255 Million Addressable Market Across Nuclear Power, Coal-Fired Utilities, and Municipal Water Treatment $1 Million in Purchase Orders Received To-Date...

CUPERTINO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Ambow Education Holding Ltd. (“Ambow”, “Ambow Education” or the “Company”) (NYSE American: AMBO), a global innovator of AI-powered phygital...

Comprehensive Value Strategy Delivering Strong Results and Returns for Shareholders Diana Shipping’s Proposal Substantially Undervalues Genco and Fails to Provide Appropriate Premium to Shareholders...

AtlasClear Holdings to Present at the Emerging Growth Conference on April 2, 2026

Westwood Real Estate Income Fund Celebrates 25-Year Anniversary

Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener...

Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses...

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...